Drug Trial Radar · NCT07430306
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
245
Planned (sponsor's estimate)
Start
Apr 13, 2026
Primary completion
Jan 26, 2029
Study completion Jan 26, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- Feb 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment. The study will also employ a tapering protocol for a systematic approach to GC tapering, seeking to understand better the proportion of patients in remission who can successfully withdraw chronic GC completely.
Conditions
- Systemic Lupus Erythematosus
Interventions
AnifrolumabDrug
Patients will receive Anifrolumab subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Attainment of DORIS remissionTime frame: At Week 52
Locations
108 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Anniston, Alabama · Withdrawn
Research Site
Birmingham, Alabama · Recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Tucson, Arizona · Recruiting
Research Site
Fontana, California · Not yet recruiting
Research Site
La Jolla, California · Recruiting
Research Site
La Palma, California · Recruiting
Research Site
Menifee, California · Recruiting
Research Site
San Leandro, California · Recruiting
Research Site
Temecula, California · Recruiting
Research Site
Brandon, Florida · Not yet recruiting
Research Site
Miami, Florida · Not yet recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Miami, Florida · Suspended
Research Site
St. Petersburg, Florida · Not yet recruiting
Research Site
Willowbrook, Illinois · Recruiting
Research Site
New Albany, Indiana · Recruiting
Research Site
Lake Charles, Louisiana · Recruiting
Research Site
Silver Spring, Maryland · Recruiting
Research Site
Kansas City, Missouri · Recruiting
Research Site
West Long Branch, New Jersey · Recruiting
Research Site
Oklahoma City, Oklahoma · Not yet recruiting
Research Site
Oklahoma City, Oklahoma · Recruiting
Research Site
Memphis, Tennessee · Not yet recruiting
Research Site
Memphis, Tennessee · Recruiting
Research Site
Austin, Texas · Not yet recruiting
Research Site
Baytown, Texas · Recruiting
Research Site
Colleyville, Texas · Recruiting
Research Site
Edinburg, Texas · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Sugar Land, Texas · Recruiting
Research Site
Spokane, Washington · Recruiting
Research Site
Calgary, Alberta, Canada · Not yet recruiting
Research Site
Richmond, British Columbia, Canada · Not yet recruiting
Research Site
Winnipeg, Manitoba, Canada · Not yet recruiting
Research Site
Hamilton, Ontario, Canada · Not yet recruiting
Research Site
Toronto, Ontario, Canada · Not yet recruiting
Research Site
Clermont-Ferrand, France · Recruiting
Research Site
Lyon, France · Recruiting
Research Site
Marseille, France · Recruiting
Showing 40 of 108 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.